Ron Leuty

Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50 - San Francisco Business Times This company put everything into one drug. Now it's cutting half of staff. Here's more on how Theravance Biopharma will close its research unit, cut staff below 50 and explore a sale after a late-stag...

Theravance to cut 50% of workforce, weigh options, including a sale, after late-stage clinical trial failure - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Thermo Fisher looks to shake up Bay Area biotech with 10-foot microscope - San Francisco Business Times A "big box" at parking garage level could give Bay Area biotech companies big answers that could help develop HIV vaccines and other drugs.

How this company hopes to reshape drug discovery and development with a 10-foot tower in a 2,300-square-foot space at parking garage level www.bizjournals.com/sanfrancisco...

More on Church & Epstein, how simple "no" could have been, making amends? - The Niche Biologist discusses the week's regenerative news including more on Church & Epstein, TX AG sues cord blood firm, losing your Y, mutations.

More on Church & Epstein, how simple "no" could have been, making amends? ipscell.com/2026/03/more... Woody Allen b-day party invite is striking

How a Talking Heads musician and a Cal Academy scientist plan to defang snake venom - San Francisco Business Times Jerry Harrison of Talking Heads helped fund Ophirex, a Corte Madera company developing the first oral snakebite treatment in over 100 years.

Singer-songwriter Jerry Harrison — best known as a keyboardist and guitarist with the legendary new wave band Talking Heads — surveyed guests at a summer garden party at his Mill Valley home: Did anyone have any fallow ideas they'd like to pursue?
www.bizjournals.com/sanfrancisco...

How a Bay Area company won a drug approval and a $2.5 billion buyout in eight years - San Francisco Business Times Day One rescued a drug from the corporate trash heap and focused it on kids with a form of brain cancer. Now its about to be bought for $2.5 billion.

How a Bay Area company won a drug approval and a $2.5 billion buyout in eight years www.bizjournals.com/sanfrancisco...

GSK reached out to buyout target's big shareholder before talking to senior leaders - San Francisco Business Times "After you take some well-deserved time off … let's do it again!" the chair of RAPT Therapeutics' board tells co-founder-CEO Brian Wong after $2.2 billion GSK deal closes

GSK's direct contact with some RAPT Therapeutics shareholders was an ongoing concern for RAPT's board ahead of the companies closing the $2.2 billion buyout www.bizjournals.com/sanfrancisco...

This 21-year-old S.F. CEO left Stanford to develop a wearable that tracks women's hormones - San Francisco Business Times "For the first time, the women in my life are feeling understood and seen": How a 21-year-old Stanford grad developed a wearable to help women track their hormones

"For the first time, the women in my life are feeling understood and seen."
Clair Health's 21-year-old CEO touts hormone-tracking wearable for women www.bizjournals.com/sanfrancisco...

The kids are alright: Old drug from BioMarin scores key win in teens - San Francisco Business Times The kids are alright: Old drug from BioMarin scores key win in teens

The kids are alright: Why BioMarin's expansion of Palynziq to teens with PKU is a big win for the company and patients www.bizjournals.com/sanfrancisco...

How Genentech uncovered an alleged scheme to ship an expensive drug into the U.S. from Canada - San Francisco Business Times It started when a package arrived at an allergy and asthma practice in suburban Detroit. That led Genentech to discover a multinational scheme to profit off of one of its products.

Genentech, Novartis claim in a suit filed last month they uncovered a scheme by a mail-order drug company to tap a Canadian pharmacy to undercut the price of Xolair in the United States
www.bizjournals.com/sanfrancisco...

Dr Oz, with Vance standing behind him, announces that "we're going to for the first time take a massive action to defer funds to a state," then details they are defending $259m of funding for Medicaid programs in Minnesota that take care of pregnant women, seniors, and people with disabilities

This is both an act of war *and* a war crime, as it is similar to cutting off water or destroying power plants. It's designed to kill civilians.

'Superheroes' at a Bay Area company just launched the first clinical trial in an autism spectrum disorder — 'Our ultimate goal is a cure' - San Francisco Business Times "Our ultimate goal is a cure. But if my son could even develop the motor ability to hold a book and turn the pages, that would be a huge win," the mother of a boy with Pitt Hopkins syndrome said of a ...

"Lucky for us, Yael remembered the Pitt Hopkins community and fought for us."
share.google/mL314xD8Q6xx...

Startups from UC Berkeley incubator cross $1 billion funding mark - San Francisco Business Times Fifty-five biotech companies connected to UC Berkeley's four-year-old incubator have collectively raised $1 billion, creating hundreds of jobs in the process. The projects represent a philosophical sh...

UC Berkeley's Bakar Labs hits $1 billion in funding for its tenants, alumni www.bizjournals.com/sanfrancisco...

BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell it - San Francisco Business Times BioMarin Pharmaceutical Inc. pulled Roctavian from the market. Sales of the hemophilia gene therapy fell drastically short of projections.

Why BioMarin pulled a cutting-edge therapy from the market www.bizjournals.com/sanfrancisco...

How a prostate cancer drug and a $1.7 billion deal landed at Vir Bio - San Francisco Business Times This cancer drug has been touched by four companies over the past four years. Now it could help some of the sickest of the sick prostate cancer patients.

How a prostate cancer drug and a potential $1.7 billion deal landed at Vir Bio www.bizjournals.com/sanfrancisco...

This Bay Area company was targeted by Congress for its Chinese ownership. Now, it will sell to a Swiss company - San Francisco Business Times This Bay Area company was targeted by Congress for having Chinese ownership. Now, it's being sold to a Swiss company.

Once targeted by Congress for its ties to China, a Bay Area biotech now will be sold to a Swiss company www.bizjournals.com/sanfrancisco...

Why Gilead plans to buy a Bay Area company for $7.8 billion - San Francisco Business Times Gilead Sciences is making one of its biggest bets on cancer treatment since acquiring cell therapy pioneer Kite Pharma in 2017. Here's why it's shelling out close to $8 billion for a blood cancer comp...

Nearly a decade after buying into the cancer cell therapy business with Kite, Gilead aims for multibillion-dollar acquisition of another company on the cusp of an FDA cell therapy decision www.bizjournals.com/sanfrancisco...

An xAI co-founder who left Elon Musk's startup last week has found his 'next chapter' - San Francisco Business Times After a rapid exodus of xAI co-founders, one of them has landed at a Peninsula company.

"He brings something rare: firsthand experience building a true rocketship." -- Integrated Bio co-founder and CEO Felix Wong on bringing on xAI co-founder Tony Wu www.bizjournals.com/sanfrancisco...

A diagnostics company moved out. Its former landlord claims it left a mess. - San Francisco Business Times A diagnostics company moved out. Its former landlord claims it left a mess

A diagnostics company moved out. Its former landlord claims it left a mess
$MYGN $DGX $DOC www.bizjournals.com/sanfrancisco...

After 30 years, Oakland's bad bet on pro sports is finally paid off. What comes next for Coliseum complex? - San Francisco Business Times No Raiders, A's or Warriors — but the Oakland Coliseum complex finally is debt-free.

Oakland finally pays off 30-year-old bet to keep Raiders, A's and Warriors in town. Hundreds of millions of dollars later, all 3 teams are gone. www.bizjournals.com/sanfrancisco...

This S.F. startup wants an IPO with two part-time employees, including a CEO who just went through bankruptcy - San Francisco Business Times A personal bankruptcy. Two industry veterans. And two potentially groundbreaking drugs. Where is this freshly filed IPO going?

Three years ago, the current CEO of this Bay Area eye drug developer filed for personal bankruptcy. Now his company is seeking a $15M IPO to take 2 drugs into clinical trials www.bizjournals.com/sanfrancisco...

Here's what Genentech plans to tear down and build on its South San Francisco campus - San Francisco Business Times In filings, Genentech has revealed exactly what structures it plans to demolish in South San Francisco, and what will replace them.

Here's what Genentech plans to tear down and what it plans to build anew in the first phase of a sweeping remake of its South San Francisco campus www.bizjournals.com/sanfrancisco...

Lyme disease tore at his family. Now he's heading an influential foundation funding research to combat the illness - San Francisco Business Times "It's not a matter of solvability," David Walsey says of his organization's battle against Lyme disease. "It's a matter of commitment and dedication."

Why heading a major #LymeDisease foundation is personal to this new boss www.bizjournals.com/sanfrancisco...

Nektar CEO looks to add $400 milllion for atopic dermatitis drug - San Francisco Business Times Balancing an important part of the immune system to resolve autoimmune diseases won a Nobel Prize last year. Now Nektar Therapeutics hopes to raise $400 million on a drug using that approach in atopic...

Nektar latest comeback: Planned late-stage clinical trial and 2029 request to approve drug for atopic dermatitis www.bizjournals.com/sanfrancisco...

Celine Halioua went to the dogs, and just dug up $100 million for her company's canine lifespan drug - San Francisco Business Times Celine Halioua went to the dogs, and just dug up $100 million for her company's canine longevity drug

If Loyal's drug is approved by the FDA — possibly next year — it would be the first drug OK'd by the agency to extend lifespan in any species, according to the company www.bizjournals.com/sanfrancisco...

Former Gilead execs' startup targets fresh funding based on fat-fighting drug's study results - San Francisco Business Times A Peninsula company launched by former Gilead Sciences Inc. executives wants to raise millions of dollars to push a fat-attacking drug closer to market.

OrsoBio, with former Gilead execs, hits target for fighting fat - San Francisco Business Times www.bizjournals.com/sanfrancisco...

'It makes a difference': Super Bowl LX means big money, big business and big dreams of more to come - San Francisco Business Times "Everything that we dreamed about became a reality," Bay Area Host Committee President and CEO Zaileen Janmohamed said of Super Bowl LX. But the dream doesn't end after the NFL event.

"In the end, everything that we dreamed about became a reality." — @bayareaHC CEO @Zaileenh on #SuperBowlLX www.bizjournals.com/sanfrancisco...

I actually predicted before the game that the MVP would go to Kenneth Walker III. But that defense was unbelievable and Myers is automatic.

How do you not give the MVP to the entire Seahawks defense?
#SuperBowlLX

That is one bad bunny!
#SuperBowlLX